RAD9

RAD9
Name	RAD9A
Altnames	RAD9, HRad9
Locus	11q13.1
Omim	603390
Uniprot	Q9Y5Q5
Organism	Homo sapiens

RAD9

Introduction

RAD9 is a eukaryotic cell cycle checkpoint protein originally characterized in Saccharomyces cerevisiae, later conserved in Schizosaccharomyces pombe and humans, acting within DNA damage surveillance pathways alongside factors such as RAD1, HUS1, ATR, ATM, CHK1, CHK2, BRCA1, and BRCA2; it participates in repair complexes linked to genomic stability in contexts studied by groups at institutions including Cold Spring Harbor Laboratory, The Sanger Institute, and MIT. Researchers have implicated RAD9 in responses to genotoxic stress from agents like ionizing radiation, UV radiation, and chemotherapeutics such as cisplatin and etoposide, with mechanistic connections to proteins studied in landmark projects like the Human Genome Project and initiatives at the National Institutes of Health.

Gene and Protein Structure

The human RAD9A gene resides at chromosome band 11q13.1 and encodes a ~389 amino acid protein with conserved domains related to 9-1-1 complex formation, sharing structural features with proteins characterized by crystallographers at facilities including the European Molecular Biology Laboratory and Brookhaven National Laboratory; its sequence conservation links to orthologs examined in Caenorhabditis elegans, Drosophila melanogaster, and vertebrates analyzed by the Ensembl and UniProt consortia. Structural studies describe RAD9 interfaces for heterotrimer assembly with RAD1 and HUS1, phospho-acceptor motifs targeted by ATR and ATM, and C-terminal regions mediating interactions with proteins such as RFC components and the DNA polymerase δ machinery; these features have been mapped using techniques developed at facilities like Stanford University and Max Planck Institute.

Function in DNA Damage Response

RAD9 functions as part of the 9-1-1 clamp that is loaded onto DNA at sites of damage by the RFC-like loader and coordinates signaling through kinases including ATR and CHK1 to enforce cell cycle arrest in G1, S, and G2 phases, a paradigm elucidated in studies from Cold Spring Harbor Laboratory and Harvard Medical School. The protein facilitates recruitment of base excision repair factors such as OGG1 and APE1 and homologous recombination mediators like RAD51 and BRCA2, integrating with pathways implicated in genome maintenance researched at institutions including UCSF and Johns Hopkins University; RAD9 also influences apoptotic outcomes via crosstalk with p53 and interactions observed in studies from The Scripps Research Institute.

Regulation and Interactions

RAD9 activity is regulated by post-translational modifications including phosphorylation by ATR, ATM, and cyclin-dependent kinases characterized by investigators at Cold Spring Harbor Laboratory and Max Planck Institute for Biochemistry, as well as by interactions with ubiquitin ligases studied in labs at University of Cambridge; binding partners include RAD1, HUS1, TOPBP1, CLASPIN, RAD17, and scaffold proteins such as BRCT-domain containing factors examined by structural groups at EMBL-EBI. Cell cycle cues from cyclins and CDK2 modulate RAD9 localization to chromatin and its turnover by proteasomal pathways involving components first defined in work at MIT and ETH Zurich; additional regulation arises from transcriptional control by factors studied at Cold Spring Harbor Laboratory and epigenetic marks profiled by consortia like the ENCODE Project.

Clinical Significance and Disease Associations

Alterations in RAD9 expression or function have been associated with cancer phenotypes characterized in cohorts from institutions including MD Anderson Cancer Center, Dana-Farber Cancer Institute, and Memorial Sloan Kettering Cancer Center, with links to tumor types such as breast cancer, lung cancer, colorectal cancer, and prostate cancer. Germline and somatic variants have been examined alongside well-known tumor suppressors and oncogenes like TP53, BRCA1, KRAS, and PIK3CA in studies funded by the National Cancer Institute; RAD9-dependent repair defects influence responses to therapies including PARP inhibitors and platinum-based chemotherapy agents evaluated in clinical trials coordinated by groups at NIH Clinical Center and cooperative groups like the NCI. Beyond oncology, RAD9 perturbation has been explored in models of aging and neurodegeneration studied at NIH and Max Planck Institute for Biology of Ageing, with potential links to DNA repair syndromes characterized in clinics at Johns Hopkins Hospital.

Experimental Models and Research Tools

Functional analysis of RAD9 has relied on genetic systems such as yeast deletion libraries at The Saccharomyces Genome Database, RNA interference screens performed at Broad Institute, CRISPR/Cas9 knockout lines developed at Addgene repositories, and mouse knockout models generated and phenotyped at institutions including The Jackson Laboratory and Wellcome Trust Sanger Institute. Biochemical assays utilize purified 9-1-1 complexes produced by labs at EMBL and structural determination via cryo-EM and X-ray crystallography at facilities like Diamond Light Source and Argonne National Laboratory; clinical and genomic datasets from The Cancer Genome Atlas and ClinVar support translational research and variant interpretation efforts led by consortia including GA4GH and the 1000 Genomes Project.

Category:DNA repair proteins